title: Multicentre study of the in vitro evaluation of moxifloxacin and other quinolones against community acquired respiratory pathogens.
abstract: The in vitro activity of moxifloxacin was compared with that of ciprofloxacin, levofloxacin, ofloxacin and trovafloxacin against 710 strains (180 Streptococcus pneumoniae, 180 Haemophilus influenzae, 160 Moraxella catarrhalis and 190 Streptococcus pyogenes) isolated from patients with community-acquired respiratory tract infections. MIC values for moxifloxacin, trovafloxacin were 0.25/0.25, 0.03/0.03, 0.06/0.03 and 0.125/0.0125 mg/l for S. pneumoniae, H. influenzae, M. catharralis and S. pyogenes. Based upon the MIC(90) values and the MIC distributions, moxifloxacin and trovafloxacin were the most active of the quinolones tested. They showed enhanced activity against Gram-positive organisms including penicillin non susceptible S. pneumoniae strains. Moxifloxacin was also highly active against ciprofloxacin-resistant S. pneumoniae strains.
authors.affiliation: Centro de Infectología, Pacheco de Melo 3068, Buenos Aires 1425, Argentina. 1hlopez@arnet.com.ar
authors.forename: H
authors.initials: H
authors.lastname: Lopez
authors.forename: V
authors.initials: V
authors.lastname: Vilches
authors.forename: S
authors.initials: S
authors.lastname: Scarano
authors.forename: D
authors.initials: D
authors.lastname: Stepanik
authors.forename: J
authors.initials: J
authors.lastname: Smayevsky
authors.forename: L
authors.initials: L
authors.lastname: Lemme
authors.forename: O
authors.initials: O
authors.lastname: Cardeñosa
authors.forename: J
authors.initials: J
authors.lastname: Ambler
authors.forename: A
authors.initials: A
authors.lastname: Sucari
mesh_terms: D000890:Anti-Infective Agents / Q000494:pharmacology*; D001372:Aza Compounds; D001419:Bacteria / Q000187:drug effects*; D002939:Ciprofloxacin / Q000494:pharmacology; D017714:Community-Acquired Infections / Q000382:microbiology*; D024841:Fluoroquinolones; D006193:Haemophilus influenzae / Q000187:drug effects; D006801:Humans; D064704:Levofloxacin; D008826:Microbial Sensitivity Tests; D001936:Moraxella catarrhalis / Q000187:drug effects; D000077266:Moxifloxacin; D009287:Naphthyridines / Q000494:pharmacology; D015242:Ofloxacin / Q000494:pharmacology; D011804:Quinolines; D012141:Respiratory Tract Infections / Q000382:microbiology*; D013296:Streptococcus pneumoniae / Q000187:drug effects; D013297:Streptococcus pyogenes / Q000187:drug effects
chemical_list: D000890:Anti-Infective Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D009287:Naphthyridines; D011804:Quinolines; D002939:Ciprofloxacin; D064704:Levofloxacin; C080163:trovafloxacin; D015242:Ofloxacin; D000077266:Moxifloxacin